IP Library Granted Patent US 8,784,889
Granted Patent B2
US 8,784,889 · App. 11/668,908 · Granted Jul 22, 2014

Graft with increased resistance to enzymatic degradation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,784,889
App. No.
11/668,908
Granted
Jul 22, 2014
Kind
B2
Abstract

Described are devices, methods, and systems for grafting tissues or organs that are exposed to bacterial or mammalian enzymes that degrade collagenous materials. Illustrative medical grafts are processed by contacting a collagenous extracellular matrix (ECM) material with a mono-carboxylic acid having from four to about twelve carbon atoms, or mixtures of two or more such acids.

Claims (8)

1. A method for preparing a medical graft product, comprising:

contacting an extracellular matrix material retaining growth factors or other bioactive components native to a source tissue for the extracellular matrix material with a mono-carboxylic acid having from four to twelve carbon atoms in an amount effective to increase resistance of the extracellular matrix material to degradation caused by enzymes relative to an untreated extracellular matrix material.

2. The method of claim 1 , wherein said extracellular matrix material comprises submucosa.

3. The method of claim 2 , wherein said submucosa comprises small intestinal submucosa.

4. The method of claim 3 , wherein said small intestinal submucosa is porcine.

5. The method claim of 4 , wherein said small intestinal submucosa is bioremodelable.

6. The method claim of 5 , wherein said mono-carboxylic acid comprises octanoic acid.

7. The method of claim 1 , wherein said mono-carboxylic acid comprises butanoic, pentanoic, hexanoic, heptanoic, octanoic, nonanoic, decanoic, hendecanoic, dodecanoic acid, or any mixtures of two or more of these acids.

Assignments (3)
SECURITY INTEREST Recorded Sep 25, 2025
From: RTI SURGICAL, INC.; COOK BIOTECH INCORPORATED; TISSX, LLC
To: GOLUB CAPITAL MARKETS LLC, AS COLLATERAL AGENT
Reel/Frame 072924/0721 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS AND TRADEMARKS Recorded Sep 25, 2025
From: ARES CAPITAL CORPORATION
To: COOK BIOTECH INCORPORATED
Reel/Frame 072938/0231 →
SECURITY INTEREST Recorded Apr 3, 2024
From: COOK BIOTECH INCORPORATED
To: ARES CAPITAL CORPORATION, AS SECURITY AGENT
Reel/Frame 067001/0541 →